Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
CureVac (CVAC)
NASDAQ:CVAC
Holding CVAC?
Track your performance easily
CVAC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.22 - $7.96
Previous Close$3.29
Volume154.19K
Average Volume (3M)793.71K
Market Cap
$753.67M
Enterprise Value$338.08M
Total Cash (Recent Filing)€402.45M
Total Debt (Recent Filing)€41.82M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Nov 14, 2024EPS Estimate
$1.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding223,988,675
10 Day Avg. Volume495,894
30 Day Avg. Volume793,706
Standard Deviation0.29
R-Squared0.20
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)1.42
Price to Sales (P/S)29.27
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.63Price Target Upside127.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
CureVac News
PremiumCompany Announcements
CureVac’s CVGBM Shows Promise in Glioblastoma Study
PremiumCompany Announcements
CureVac-GSK Influenza Vaccine Shows Promise
PremiumCompany Announcements
CureVac Unveils Promising Glioblastoma Vaccine Data
PremiumCompany Announcements
CureVac Secures Lucrative GSK Deal and Refocuses BusinessBulls Say, Bears Say
Bulls Say
Clinical TrialsThe first patient was dosed in the dose expansion part of the ongoing Phase 1 trial for CureVac’s multiepitope cancer vaccine candidate, CVGBM, in patients with resected glioblastoma.
Financial PerformanceCureVac reported 2Q24 results, ending the quarter with €202.5M and receiving the €400M upfront from GSK for COVID-19/flu in August, bringing estimated pro forma cash to €602.5M.
Strategic RestructuringCureVac announced modification of its GSK collaboration, internal restructuring to prioritize oncology and other selected diseases, and a 30% workforce reduction.
Bears Say
Financial PerformanceCash was impacted by over €80M due to continued resolution of obligations from the first-gen COVID-19 vaccine.
ManagementCVAC announced the departure of its CFO.
Product OpportunityThere is likely not a meaningful opportunity for a new standalone COVID vaccine.
---
Ownership Overview
0.00% Insiders
1.18% Mutual Funds
2.54% Other Institutional Investors
96.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CVAC FAQ
What was CureVac’s price range in the past 12 months?
CureVac lowest stock price was $2.21 and its highest was $7.96 in the past 12 months.
What is CureVac’s market cap?
Currently, no data Available
When is CureVac’s upcoming earnings report date?
CureVac’s upcoming earnings report date is Nov 14, 2024 which is in 56 days.
How were CureVac’s earnings last quarter?
CureVac released its earnings results on Aug 15, 2024. The company reported -$0.355 earnings per share for the quarter, missing the consensus estimate of -$0.312 by -$0.043.
Is CureVac overvalued?
According to Wall Street analysts CureVac’s price is currently Undervalued.
Does CureVac pay dividends?
CureVac does not currently pay dividends.
What is CureVac’s EPS estimate?
CureVac’s EPS estimate is $1.57.
How many shares outstanding does CureVac have?
CureVac has 224,305,680 shares outstanding.
What happened to CureVac’s price movement after its last earnings report?
CureVac reported an EPS of -$0.355 in its last earnings report, missing expectations of -$0.312. Following the earnings report the stock price went down -1.813%.
Which hedge fund is a major shareholder of CureVac?
Among the largest hedge funds holding CureVac’s share is Platinum Investment Management. It holds CureVac’s shares valued at N/A.
---
CureVac Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.63 (127.08% Upside)
$7.63 (127.08% Upside)
Blogger Sentiment
Bearish
CVAC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.60%
12-Months-Change
Fundamentals
Return on Equity
-54.12%
Trailing 12-Months
Asset Growth
-39.19%
Trailing 12-Months
Company Description
CureVac
CureVac BV a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.
---
CVAC Company Deck
---
CVAC Earnings Call
Q4 2024
0:00 / 0:00
---
CVAC Stock 12 Month Forecast
Average Price Target
$7.63
▲(127.08% Upside)
Technical Analysis
Best Analysts Covering CVAC
1 Year
1 Year Success Rate
4/24 ratings generated profit
1 Year Average Return
-34.33%
reiterated a buy rating 4 days ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -34.33% per trade.
---